[Psychotic disorders linked to the inhibition of benzodiazepine catabolism].
Five clinical cases of interaction between benzodiazepines on one hand and erythromycin, troleandomycin, josamycin and cimetidine on the other hand have been analyzed. These interactions resulted in severe disorders of behaviour, amnesia (including amnesia-automatism syndrome in one case), disturbances of consciousness and withdrawal syndrome. These disorders were consecutive to inhibition of the hepatic cytochrome P-450 system. Practical means of avoiding this risk consists in limiting such drug combinations, reducing benzodiazepine dosage and, if a combined treatment is necessary, using by preference either benzodiazepines degraded by conjugation instead of oxidation, or macrolides, or anti-H2 compounds with reduced inhibitory effect on microsomes.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects* / Q000378:metabolism; D001569:Benzodiazepines; D002927:Cimetidine / Q000009:adverse effects; D004347:Drug Interactions; D004917:Erythromycin / Q000009:adverse effects; D005260:Female; D006801:Humans; D007933:Leucomycins / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011605:Psychoses, Substance-Induced / Q000209:etiology*; D014217:Troleandomycin / Q000009:adverse effects
D014151:Anti-Anxiety Agents; D007933:Leucomycins; D001569:Benzodiazepines; D004917:Erythromycin; D002927:Cimetidine; D014217:Troleandomycin
Accidents psychiques liés à l'inhibition du catabolisme des benzodiazépines.